The DOI matches its Crossref record; 336 of the 336 references it cites were found in a registry or an index.
Immunology of COVID-19: Current State of the Science
Open accessAbstract
The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected millions of people worldwide, igniting an unprecedented effort from the scientific community to understand the biological underpinning of COVID19 pathophysiology. In this Review, we summarize the current state of knowledge of innate and adaptive immune responses elicited by SARS-CoV-2 infection and the immunological pathways that likely contribute to disease severity and death. We also discuss the rationale and clinical outcome of current therapeutic strategies as well as prospective clinical trials to prevent or treat SARS-CoV-2 infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among them, IL-6 is a major player in chronic inflammatory diseases, autoimmune diseases, cancer and cytokine storm (1, 3, 10–26).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“ARDS in COVID-19 is considered the result of cytokine storm (12–17), resembling the disease caused by SARS-CoV-1 and Middle East respiratory syndrome coronavirus (MERS-CoV) (335).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“Consistent with the notion that severe COVID-19 is a cytokine storm syndrome (12–17, 336), the severity of COVID-19 is associated with an increased level of inflammatory cytokines, such as IL-6, granulocyte macrophage colony-stimulating factor (GM-CSF) and TNFα (333, 337).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [17]
In the citing paper
“There is currently no defined correlate of protection against COVID-19 or SARS-CoV-2 infection, and as such the immunological thresholds required for vaccine efficacy have not yet been defined163.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [163]
In the citing paper
“the host itself seems to be the major factor explaining disease severity, infection rates (Merad and Martin, 2020; Vabret et al., 2020), and long-term medical consequences (Marshall, 2020).”
From COVID-19 and the human innate immune system (2021) · cites this paper as Vabret et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Gautret, P., Lagier, J., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Esteves-Vieira, V., et al. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105949 · Cited by 5,288
RetractedSiu, K., Yeung, M. L., Kok, K., Yuen, K., Kew, C., Lui, P., Chan, C., Tse, H., Woo, P. C. Y., Yuen, K., et al. (2014) · Journal of Virology · doi:10.1128/jvi.03649-13 · Cited by 179
RetractedClinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30251-8 · Cited by 11,907
COVID-19: consider cytokine storm syndromes and immunosuppression
Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30628-0 · Cited by 9,664
Self-citationStructure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
Pathological findings of COVID-19 associated with acute respiratory distress syndrome
Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., Liu, S., Zhao, P., Liu, H., Zhu, L., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30076-x · Cited by 8,545
Wu, C., Chen, X., Cai, Y., Xia, J., Zhou, X., Xu, S., Huang, H., Zhang, L., Zhou, X., Du, C., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.0994 · Cited by 8,249
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hú, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,994
Virological assessment of hospitalized patients with COVID-2019
Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A., Niemeyer, D., Jones, T. C., Vollmar, P., Rothe, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2196-x · Cited by 6,661
Endothelial cell infection and endotheliitis in COVID-19
Varga, Z., Flammer, A. J., Steiger, P., Haberecker, M., Andermatt, R., Zinkernagel, A. S., Mehra, M. R., Schuepbach, R. A., Ruschitzka, F., & Moch, H. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30937-5 · Cited by 6,358
Tang, N., Li, D., Wang, X., & Sun, Z. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14768 · Cited by 5,770
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001282 · Cited by 5,258
Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China
Qin, C., Zhou, L., Hu, Z., Zhang, S., Yang, S., Tao, Y., Xie, C., Ma, K., Shang, K., Wang, W., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa248 · Cited by 4,775
Clinical and immunological features of severe and moderate coronavirus disease 2019
Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T., Zhang, X., Chen, H., Yu, H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137244 · Cited by 4,750
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
Gordon, D. E., Jang, G. M., Bouhaddou, M., Xu, J., Obernier, K., White, K. M., O’Meara, M. J., Rezelj, V. V., Guo, J. Z., Swaney, D. L., et al. (2020) · Nature · doi:10.1038/s41586-020-2286-9 · Cited by 4,405
Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China
Shi, S., Qin, M., Shen, B., Cai, Y., Liu, T., Yang, F., Gong, W., Liu, X., Liang, J., Zhao, Q., et al. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.0950 · Cited by 4,349
Wan, Y., Shang, J., Graham, R., Baric, R. S., & Li, F. (2020) · Journal of Virology · doi:10.1128/jvi.00127-20 · Cited by 4,341
Self-citationImbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19
Blanco-Melo, D., Nilsson-Payant, B. E., Liu, W.-C., Uhl, S., Hoagland, D., Møller, R., Jordan, T. X., Oishi, K., Panis, M., Sachs, D., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.026 · Cited by 4,222
SARS and MERS: recent insights into emerging coronaviruses
de Wit, E., van Doremalen, N., Falzarano, D., & Munster, V. J. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.81 · Cited by 3,510
Wang, Y., Zhang, D., Du, G., Du, R., Zhao, J., Jin, Y., Fu, S., Gao, L., Cheng, Z., Lu, Q., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31022-9 · Cited by 3,442
Wynants, L., Van Calster, B., Bonten, M. M., Collins, G. S., Debray, T. P., De Vos, M., Haller, M. C., Heinze, G., Moons, K. G., Riley, R. D., et al. (2020) · doi:10.1101/2020.03.24.20041020 · Cited by 3,070
To, K. K., Tsang, O. T.-Y., Leung, W.-S., Tam, A. R., Wu, T.-C., Lung, D. C., Yip, C. C., Cai, J., Chan, J. M., Chik, T. S., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30196-1 · Cited by 3,045
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
Hadjadj, J., Yatim, N., Barnabei, L., Corneau, A., Boussier, J., Smith, N., Péré, H., Charbit, B., Bondet, V., Chenevier-Gobeaux, C., et al. (2020) · Science · doi:10.1126/science.abc6027 · Cited by 2,984
Compassionate Use of Remdesivir for Patients with Severe Covid-19
Grein, J. D., Ohmagari, N., Shin, D., Diaz, G., Asperges, E., Castagna, A., Feldt, T., Green, G., Green, M. L., Lescure, F.-X., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007016 · Cited by 2,739
Yao, X., Ye, F., Zhang, M., Cui, C., Huang, B., Niu, P., Liu, X., Zhao, L. Y., Dong, E., Song, C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa237 · Cited by 2,696
Effective treatment of severe COVID-19 patients with tocilizumab
Xu, X., Han, M., Li, T., Sun, W., Wang, D., Fu, B., Zhou, Y., Zheng, X., Yang, Y., Li, X., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2005615117 · Cited by 2,670
Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19
Liao, M., Liu, Y., Yuan, J., Wen, Y., Xu, G., Zhao, J., Cheng, L., Li, J., Wang, X., Wang, F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0901-9 · Cited by 2,614
Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019
Zhao, J., Yuan, Q., Wang, H., Liu, W., Liao, X., Su, Y., Wang, X., Yuan, J., Li, T., Li, J., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa344 · Cited by 2,607
An inflammatory cytokine signature predicts COVID-19 severity and survival
Del Valle, D. M., Kim-Schulze, S., Huang, H.-H., Beckmann, N. D., Nirenberg, S., Wang, B., Lavin, Y., Swartz, T. H., Madduri, D., Stock, A., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1051-9 · Cited by 2,605
Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)
Diao, B., Wang, C., Tan, Y., Chen, X., Liu, Y., Ning, L., Chen, L., Li, M., Liu, Y., Wang, G., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00827 · Cited by 2,475
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)
Sanders, J. M., Monogue, M. L., Jodlowski, T. Z., & Cutrell, J. B. (2020) · JAMA · doi:10.1001/jama.2020.6019 · Cited by 2,392
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma
Shen, C., Wang, Z., Zhao, F., Yang, Y., Li, J., Yuan, J., Wang, F., Li, D., Yang, M., Xing, L., et al. (2020) · JAMA · doi:10.1001/jama.2020.4783 · Cited by 2,298
Ziegler, C. G. K., Allon, S. J., Nyquist, S. K., Mbano, I. M., Miao, V. N., Tzouanas, C. N., Cao, Y., Yousif, A. S., Bals, J., Hauser, B. M., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.035 · Cited by 2,284
HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C
Braud, V. M., Allan, D., O'Callaghan, C. A., Söderström, K., D’Andrea, A., Ogg, G. S., Lazetic, S., Young, N. T., Bell, J. I., Phillips, J. H., et al. (1998) · Nature · doi:10.1038/35869 · Cited by 2,226
Innate Lymphoid Cells: 10 Years On
Vivier, É., Artis, D., Colonna, M., Diefenbach, A., Santo, J. P. D., Eberl, G., Koyasu, S., Locksley, R. M., McKenzie, A. N. J., Mebius, R. E., et al. (2018) · Cell · doi:10.1016/j.cell.2018.07.017 · Cited by 2,136
Liu, J., Cao, R., Xu, M., Wang, X., Zhang, H., Hu, H., Li, Y., Hú, Z., Zhong, W., & Wang, M. (2020) · Cell Discovery · doi:10.1038/s41421-020-0156-0 · Cited by 2,091
Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure
Giamarellos-Bourboulis, E. J., Netea, M. G., Rovina, N., Akinosoglou, K., Antoniadou, A., Antonakos, N., Damoraki, G., Gkavogianni, T., Adami, M.-E., Katsaounou, P., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.04.009 · Cited by 2,045
The COVID-19 vaccine development landscape
Le, T. T., Andreadakis, Z., Kumar, A., Román, R. G., Tollefsen, S., Saville, M. K., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 2,002
Covid-19 — Navigating the Uncharted
Fauci, A. S., Lane, H. C., & Redfield, R. (2020) · New England Journal of Medicine · doi:10.1056/nejme2002387 · Cited by 1,983
Effectiveness of convalescent plasma therapy in severe COVID-19 patients
Duan, K., Liu, B., Li, C., Zhang, H., Yu, T., Qu, J., Zhou, M., Chen, L., Meng, S., Hu, Y., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2004168117 · Cited by 1,968
Self-citationCytokine release syndrome in severe COVID-19
Moore, J. B., & June, C. H. (2020) · Science · doi:10.1126/science.abb8925 · Cited by 1,912
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
Vincent, M. J., Bergeron, É., Benjannet, S., Erickson, B. R., Rollin, P. E., Ksiazek, T. G., Seidah, N. G., & Nichol, S. T. (2005) · Virology Journal · doi:10.1186/1743-422x-2-69 · Cited by 1,831
A serological assay to detect SARS-CoV-2 seroconversion in humans
Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T. H. O., Chromikova, V., McMahon, M., Jiang, K., Arunkumar, G. A., Jurczyszak, D., Polanco, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0913-5 · Cited by 1,769
Self-citationFunctional exhaustion of antiviral lymphocytes in COVID-19 patients
Zheng, M., Gao, Y., Wang, G., Song, G., Liu, S., Sun, D., Xu, Y., & Tian, Z. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0402-2 · Cited by 1,768 · cited 36×
“RdRp Inhibitors The CoV RNA-dependent RNA polymerase (RdRp) catalyzes the synthesis of viral RNA (Gao et al., 2020a), making it essential for viral replication and a prime target for antiviral inhibitors.”
InfluentialSheahan, T. P., Sims, A. M., Leist, S. R., Schäfer, A., Won, J. J., Brown, A. J., Montgomery, S. A., Hogg, A., Babusis, D. M., Clarke, M. O., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13940-6 · Cited by 1,757
Hematological findings and complications of COVID ‐19
Terpos, E., Ntanasis‐Stathopoulos, I., Elalamy, I., Kastritis, E., Sergentanis, T. Ν., Politou, M., Ψαλτοπούλου, Θ., Gerotziafas, G., & Dimopoulos, M. A. (2020) · American Journal of Hematology · doi:10.1002/ajh.25829 · Cited by 1,754
Structural and functional analysis of a potent sarbecovirus neutralizing antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · doi:10.1101/2020.04.07.023903 · Cited by 1,752
Liu, J., Li, S., Liu, J., Liang, B., Wang, X., Wang, H., Li, W., Tong, Q., Yi, J., Zhao, L., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102763 · Cited by 1,726
Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study
Tan, L., Wang, Q., Zhang, D., Jinya, D., Huang, Q., Wang, Q., Wang, Q., & Miao, H. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0148-4 · Cited by 1,722
Disease Tolerance as a Defense Strategy
Medzhitov, R., Schneider, D. S., & Soares, M. P. (2012) · Science · doi:10.1126/science.1214935 · Cited by 1,718
The spike protein of SARS-CoV — a target for vaccine and therapeutic development
Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B.-J., & Jiang, S. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2090 · Cited by 1,678
Human neutralizing antibodies elicited by SARS-CoV-2 infection
Ju, B., Zhang, Q., Ge, J., Wang, R., Sun, J., Ge, X., Yu, J., Shan, S., Zhou, B., Song, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2380-z · Cited by 1,667 · cited 1×
“…providing data regarding antigen presentation and antibody-binding properties and one study looking into the predicted evolution of epitopes (Ahmed et al., 2020; Baruah and Bose, 2020; Bhattacharya et al., 2020; Fast et al., 2020; Grifoni et al., 2020; Lon et al., 2020; Zheng and Song, 2020).”
Tai, W., He, L., Zhang, X., Pu, J., Voronin, D., Jiang, S., Zhou, Y., & Du, L. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0400-4 · Cited by 1,654
Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings
Chu, C. (2004) · Thorax · doi:10.1136/thorax.2003.012658 · Cited by 1,637
Okba, N. M. A., Müller, M. A., Li, W., Wang, C., GeurtsvanKessel, C. H., Corman, V. M., Lamers, M. M., Sikkema, R. S., de Bruin, E., Chandler, F. D., et al. (2020) · Emerging Infectious Diseases · doi:10.3201/eid2607.200841 · Cited by 1,614
COVID-19: immunopathology and its implications for therapy
Cao, X. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0308-3 · Cited by 1,609
Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
Sheahan, T. P., Sims, A. M., Graham, R. L., Menachery, V. D., Gralinski, L. E., Case, J. B., Leist, S. R., Pyrć, K., Feng, J. Y., Trantcheva, I., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3653 · Cited by 1,575
Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease
Dai, W., Zhang, B., Jiang, X.-M., Su, H., Li, J., Zhao, Y., Xie, X., Jin, Z., Peng, J., Liu, F., et al. (2020) · Science · doi:10.1126/science.abb4489 · Cited by 1,517
Targeting potential drivers of COVID-19: Neutrophil extracellular traps
Barnes, B. J., Adrover, J. M., Baxter-Stoltzfus, A., Borczuk, A., Cools-Lartigue, J., Crawford, J. M., Daßler-Plenker, J., Guerci, P., Huynh, C., Knight, J. S., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20200652 · Cited by 1,486
Mechanisms of action of hydroxychloroquine and chloroquine:implications for rheumatology
Schrezenmeier, E., & Dörner, T. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0372-x · Cited by 1,468
Development of an inactivated vaccine candidate for SARS-CoV-2
Gao, Q., Bao, L., Mao, H., Wang, L., Xu, K., Yang, M., Li, Y., Zhu, L., Wang, N., Lv, Z., et al. (2020) · Science · doi:10.1126/science.abc1932 · Cited by 1,434
A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV
Yuan, M., Wu, N. C., Zhu, X., Lee, C.-C. D., So, R. T. Y., Lv, H., Mok, C. K. P., & Wilson, I. A. (2020) · Science · doi:10.1126/science.abb7269 · Cited by 1,429
Agostini, M. L., Andres, E. L., Sims, A. M., Graham, R. L., Sheahan, T. P., Lu, X., Smith, E. C., Case, J. B., Feng, J. Y., Jordan, R., et al. (2018) · mBio · doi:10.1128/mbio.00221-18 · Cited by 1,418
Channappanavar, R., Fehr, A. R., Vijay, R., Mack, M., Zhao, J., Meyerholz, D. K., & Perlman, S. M. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.01.007 · Cited by 1,400
SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19
Braun, J., Loyal, L., Frentsch, M., Wendisch, D., Georg, P., Kurth, F., Hippenstiel, S., Dingeldey, M., Kruse, B., Fauchere, F., et al. (2020) · Nature · doi:10.1038/s41586-020-2598-9 · Cited by 1,310
Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients
Zhou, Y., Fu, B., Zheng, X., Wang, D., Zhao, C., Qi, Y., Sun, R., Tian, Z., Xu, X., & Wei, H. (2020) · National Science Review · doi:10.1093/nsr/nwaa041 · Cited by 1,295
From SARS to MERS, Thrusting Coronaviruses into the Spotlight
Song, Z., Xu, Y., Bao, L., Zhang, L., Yü, P., Qu, Y., Zhu, H., Zhao, W., Han, Y., & Qin, C. (2019) · Viruses · doi:10.3390/v11010059 · Cited by 1,292
Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus
Monticelli (2011) · PubMed · doi:10.1031/ni.2131 · Cited by 1,286
Effects of chloroquine on viral infections: an old drug against today's diseases
Savarino, A., Boelaert, J. R., Cassone, A., Majori, G., & Cauda, R. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00806-5 · Cited by 1,272
Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome
Wong, C. K., LAM, C. W. K., Wu, A. K. L., Ip, W., Lee, N. L. S., Chan, I., Lit, L. C. W., Hui, D. S. C., Chan, M. H. M., CHUNG, S. S. C., et al. (2004) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2004.02415.x · Cited by 1,270
The twilight of immunity: emerging concepts in aging of the immune system
Nikolich-Žugich, J. (2018) · Nature Immunology · doi:10.1038/s41590-017-0006-x · Cited by 1,240
Tian, X., Li, C., Huang, A., Xia, S., Lu, S., Shi, Z., Lu, L., Jiang, S., Yang, Z., Wu, Y., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1729069 · Cited by 1,239
CD69 acts downstream of interferon-α/β to inhibit S1P1 and lymphocyte egress from lymphoid organs
Shiow, L. R., Rosen, D. B., Brdičková, N., Xu, Y., An, J., Lanier, L. L., Cyster, J. G., & Matloubian, M. (2006) · Nature · doi:10.1038/nature04606 · Cited by 1,189
Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19
Herold, T., Jurinovic, V., Arnreich, C., Lipworth, B. J., Hellmuth, J. C., von Bergwelt-Baildon, M., Klein, M., & Weinberger, T. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.05.008 · Cited by 1,161
Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia
Wang, F., Nie, J., Wang, H., Zhao, Q., Xiong, Y., Deng, L., Song, S., Ma, Z., Mo, P., & Zhang, Y. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa150 · Cited by 1,149
A human monoclonal antibody blocking SARS-CoV-2 infection
Wang, C., Li, W., Drabek, D., Okba, N. M. A., van Haperen, R., Osterhaus, A. D. M. E., van Kuppeveld, F. J. M., Haagmans, B. L., Grosveld, F. G., & Bosch, B. (2020) · Nature Communications · doi:10.1038/s41467-020-16256-y · Cited by 1,128
Ahmed, S. F., Quadeer, A. A., & McKay, M. R. (2020) · Viruses · doi:10.3390/v12030254 · Cited by 1,128
The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice
Bao, L., Deng, W., Huang, B., Gao, H., Liu, J., Ren, L., Wei, Q., Yu, P., Xu, Y., Qi, F., et al. (2020) · Nature · doi:10.1038/s41586-020-2312-y · Cited by 1,126
SARS-CoV-2 Vaccines: Status Report
Amanat, F., & Krammer, F. (2020) · Immunity · doi:10.1016/j.immuni.2020.03.007 · Cited by 1,120
Self-citationHuman susceptibility and resistance to Norwalk virus infection
Lindesmith, L. C., Moe, C. L., Marionneau‐Lambot, S., Ruvoën‐Clouet, N., Jiang, X., Lindblad, L., Stewart, P. W., Pendu, J. L., & Baric, R. S. (2003) · Nature Medicine · doi:10.1038/nm860 · Cited by 1,119
Liu, J., Liu, Y., Xiang, P., Pu, L., Xiong, H., Li, C., Zhang, M., Tan, J., Xu, Y., Song, R., et al. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02374-0 · Cited by 1,105
Self-citationDetection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals
Ni, L., Ye, F., Cheng, M., Yu, F., Deng, Y., Zhao, H. J., Peng, W., Ge, J., Gou, M., Li, X., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.04.023 · Cited by 1,085
Borba, M. G. S., Val, F. F. A., Sampaio, V. S., Alexandre, M. A. A., Melo, G. C., Brito, M., Mourão, M. P. G., Brito-Sousa, J. D., Baía-da-Silva, D., Guerra, M. V. F., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.8857 · Cited by 1,038
Knoops, K., Kikkert, M., van den Worm, S. H. E., Zevenhoven-Dobbe, J. C., van der Meer, Y., Koster, A. J., Mommaas, A. M., & Snijder, E. J. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060226 · Cited by 1,033
(2020) · Nature Communications · doi:10.1101/2020.04.14.20065771 · Cited by 1,019
Thevarajan, I., Nguyen, T. H. O., Koutsakos, M., Druce, J. D., Caly, L., van de Sandt, C. E., Jia, X., Nicholson, S. R., Catton, M. C., Cowie, B., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0819-2 · Cited by 993
[A pathological report of three COVID-19 cases by minimal invasive autopsies].
Yao, X. H., Li, T. Y., He, Z. C., Ping, Y. F., Liu, H. W., Yu, S. C., Mou, H. M., Wang, L. H., Zhang, H. R., Fu, W. J., et al. (2020) · PubMed · doi:10.3760/cma.j.cn112151-20200312-00193 · Cited by 963
Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies
Tian, S., Xiong, Y., Liu, H., Niu, L., Guo, J., Liao, M., & Xiao, S. (2020) · Modern Pathology · doi:10.1038/s41379-020-0536-x · Cited by 961
Use of convalescent plasma therapy in SARS patients in Hong Kong
Cheng, Y., Wong, R. S. M., Soo, Y. O. Y., Wong, W. S., Lee, C. K., Ng, M. H. L., Chan, P. K. S., Wong, K. C., Leung, C. B., & Cheng, G. Y.-M. (2004) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-004-1271-9 · Cited by 953
Zheng, H.-Y., Zhang, M., Yang, C.-X., Zhang, N., Wang, X.-C., Yang, X.-P., Dong, X.-Q., & Zheng, Y.-T. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0401-3 · Cited by 940
Grifoni, A., Sidney, J., Zhang, Y., Scheuermann, R. H., Peters, B., & Sette, A. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.03.002 · Cited by 920
Weiskopf, D., Schmitz, K. S., Raadsen, M. P., Grifoni, A., Okba, N. M. A., Endeman, H., van den Akker, J. P. C., Molenkamp, R., Koopmans, M. P. G., van Gorp, E. C. M., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abd2071 · Cited by 907
de Wit, E., Feldmann, F., Cronin, J., Jordan, R., Okumura, A., Thomas, T., Scott, D. P., Cihlář, T., & Feldmann, H. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1922083117 · Cited by 888
Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination
Pardi, N., Hogan, M. J., Pelc, R. S., Muramatsu, H., Andersen, H., DeMaso, C. R., Dowd, K. A., Sutherland, L. L., Scearce, R. M., Parks, R., et al. (2017) · Nature · doi:10.1038/nature21428 · Cited by 884
Natural killer cells, viruses and cancer
Cerwenka, A., & Lanier, L. L. (2001) · Nature reviews. Immunology · doi:10.1038/35095564 · Cited by 874
Yang, Y., Shen, C., Li, J., Yuan, J., Wei, J., Huang, F., Wang, F., Li, G., Li, Y., Xing, L., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.04.027 · Cited by 872
Cao, Y., Li, L., Feng, Z., Wan, S., Huang, P., Sun, X., Wen, F., Huang, X., Ning, G., & Wang, W. (2020) · Cell Discovery · doi:10.1038/s41421-020-0147-1 · Cited by 865
Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trialPreprint
Chen, Z., Hu, J., Zhang, Z., Jiang, S., Han, S., Yan, D., Zhuang, R., Hu, B., & Zhang, Z. (2020) · medRxiv · doi:10.1101/2020.03.22.20040758 · Cited by 861
Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial
Chen, C., Zhang, Y., Huang, J., Yin, P., Cheng, Z., Wu, J., Chen, S., Zhang, Y., Chen, B., Lu, M., et al. (2020) · doi:10.1101/2020.03.17.20037432 · Cited by 852
Self-citationLiu, L., Wei, Q., Lin, Q., Fang, J., Wang, H., Kwok, H., Tang, H., Nishiura, K., Peng, J., Tan, Z., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.123158 · Cited by 830
Tissue residency of innate lymphoid cells in lymphoid and nonlymphoid organs
Gasteiger, G., Fan, X., Dikiy, S., Lee, S. Y., & Rudensky, A. Y. (2015) · Science · doi:10.1126/science.aac9593 · Cited by 813
Chang, Y., Kim, H. Y., Albacker, L. A., Baumgarth, N., McKenzie, A. N. J., Smith, D. E., DeKruyff, R. H., & Umetsu, D. T. (2011) · Nature Immunology · doi:10.1038/ni.2045 · Cited by 797
Gautret, P., Lagier, J., Parola, P., Hoang, V. T., Meddeb, L., Sevestre, J., Mailhe, M., Doudier, B., Aubry, C., Amrane, S., et al. (2020) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2020.101663 · Cited by 775
COVID-19: a new virus, but a familiar receptor and cytokine release syndrome
Hirano, T., & Murakami, M. (2020) · Immunity · doi:10.1016/j.immuni.2020.04.003 · Cited by 772
Trimble, C. L., Morrow, M. P., Kraynyak, K. A., Shen, X., Dallas, M. J., Yan, J., Edwards, L., Parker, R. L., Denny, L., Giffear, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00239-1 · Cited by 754
Wu, F., Wang, A., Liu, M., Wang, Q., Chen, J., Xia, S., Ling, Y., Zhang, Y., Xun, J., Lu, L., et al. (2020) · doi:10.1101/2020.03.30.20047365 · Cited by 754
Molina, J., Delaugerre, C., LeGoff, J., Melo‐Lima, B. L., Ponscarme, D., Goldwirt, L., & Castro, N. D. (2020) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2020.03.006 · Cited by 747
Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing
Wen, W., Su, W., Tang, H., Le, W., Zhang, X., Zheng, Y., Liu, X., Xie, L., Li, J., Ye, J., et al. (2020) · Cell Discovery · doi:10.1038/s41421-020-0168-9 · Cited by 730
Immunotherapeutic Implications of Il-6 Blockade for Cytokine Storm
Tanaka, T., Narazaki, M., & Kishimoto, T. (2016) · Immunotherapy · doi:10.2217/imt-2016-0020 · Cited by 719
Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2
Nie, J., Li, Q., Wu, J., Zhao, C., Hao, H., Liu, H., Zhang, L., Nie, L., Qin, H., Wang, M., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1743767 · Cited by 711
Traggiai, E., Becker, S., Subbarao, K., Kolesnikova, L., Uematsu, Y., Gismondo, M. R., Murphy, B. R., Rappuoli, R., & Lanzavecchia, A. (2004) · Nature Medicine · doi:10.1038/nm1080 · Cited by 697
C-reactive protein levels in the early stage of COVID-19
Wang, L. (2020) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2020.03.007 · Cited by 684
Hung, I. F., To, K. K., Lee, C. K., Lee, K., Chan, K., Yan, W.-W., Liu, R. W., Watt, C., Chan, W.-M., Lai, K., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq106 · Cited by 679
Lo, B., Zhang, K., Lü, W., Zheng, L., Zhang, Q., Kanellopoulou, C., Zhang, Y., Liu, Z., Fritz, J. M., Marsh, R. A., et al. (2015) · Science · doi:10.1126/science.aaa1663 · Cited by 678
Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry
Wan, Y., Shang, J., Sun, S., Tai, W., Chen, J., Geng, Q., He, L., Chen, Y., Wu, J., Shi, Z., et al. (2019) · Journal of Virology · doi:10.1128/jvi.02015-19 · Cited by 673
Self-citationKopecky-Bromberg, S. A., Martínez‐Sobrido, L., Frieman, M. B., Baric, R. S., & Palese, P. (2006) · Journal of Virology · doi:10.1128/jvi.01782-06 · Cited by 662
[A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19].
Chen, J., Liu, D., Liu, L., Liu, P., Xu, Q., Xia, L., Ling, Y., Huang, D. F., Song, S., Zhang, D., et al. (2020) · PubMed Central · doi:10.3785/j.issn.1008-9292.2020.03.03 · Cited by 662
Chu, H., Chan, J. F., Wang, Y., Yuen, T. T., Chai, Y., Hou, Y., Shuai, H., Yang, D., Hu, B., Huang, X., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa410 · Cited by 659
In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine
Keyaerts, E., Vijgen, L., Maes, P., Neyts, J. H., & Ranst, M. A. V. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.08.085 · Cited by 644
Meta-Analysis: Convalescent Blood Products for Spanish Influenza Pneumonia: A Future H5N1 Treatment?
Luke, T. C., Kilbane, E. M., Jackson, J. L., & Hoffman, S. L. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-8-200610170-00139 · Cited by 642
Huang, I., Bailey, C. C., Weyer, J. L., Radoshitzky, S. R., Becker, M. M., Chiang, J. J., Brass, A. L., Ahmed, A. A., Chī, X., Dŏng, L., et al. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1001258 · Cited by 627
Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies
Wrapp, D., De Vlieger, D., Corbett, K. S., Torres, G. M., Wang, N., Van Breedam, W., Roose, K., van Schie, L., Hoffmann, M., Pöhlmann, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.031 · Cited by 610
On the use of corticosteroids for 2019-nCoV pneumonia
Shang, L., Zhao, J., Hu, Y., Du, R., & Cao, B. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30361-5 · Cited by 604
The time course of the immune response to experimental coronavirus infection of man
Callow, K. A., Parry, H. F., Sergeant, M., & Tyrrell, D. A. J. (1990) · Epidemiology and Infection · doi:10.1017/s0950268800048019 · Cited by 598
Platelet‐to‐lymphocyte ratio is associated with prognosis in patients with coronavirus disease‐19
Qu, R., Ling, Y., Zhang, Y., Wei, L., Chen, X., Li, X., Liu, X., Liu, H., Guo, Z., Ren, H., et al. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25767 · Cited by 594
Wan, S., Yi, Q., Fan, S., Lv, J., Zhang, X., Guo, L., Lang, C., Xiao, Q., Xiao, K., Yi, Z., et al. (2020) · doi:10.1101/2020.02.10.20021832 · Cited by 562
Severe Acute Respiratory Syndrome Coronavirus Viroporin 3a Activates the NLRP3 Inflammasome
Chen, I.-Y., Moriyama, M., Chang, M., & Ichinohe, T. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00050 · Cited by 562
IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes
Channappanavar, R., Fehr, A. R., Zheng, J. H., Wohlford-Lenane, C., Abrahante, J. E., Mack, M., Sompallae, R. R., McCray, P. B., Meyerholz, D. K., & Perlman, S. M. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126363 · Cited by 556
Sui, J., Li, W., Murakami, A., Tamin, A., Matthews, L. J., Wong, S. K., Moore, M. J., Tallarico, A. S. C., Olurinde, M., Choe, H., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307140101 · Cited by 542
Developing a new class of engineered live bacterial therapeutics to treat human diseases
Charbonneau, M. R., Isabella, V. M., Li, N., & Kurtz, C. B. (2020) · Nature Communications · doi:10.1038/s41467-020-15508-1 · Cited by 523
Frieman, M. B., Yount, B. L., Heise, M. T., Kopecky-Bromberg, S. A., Palese, P., & Baric, R. S. (2007) · Journal of Virology · doi:10.1128/jvi.01012-07 · Cited by 509
Nieto-Torres, J. L., Verdiá-Báguena, C., Jiménez-Guardeño, J. M., Regla-Nava, J. Á., Castaño-Rodríguez, C., Fernández‐Delgado, R., Torres, J., Aguilella, V. M., & Enjuanes, L. (2015) · Virology · doi:10.1016/j.virol.2015.08.010 · Cited by 506
Immunopathogenesis of coronavirus infections: implications for SARS
Dandekar, A. A., & Perlman, S. M. (2005) · Nature reviews. Immunology · doi:10.1038/nri1732 · Cited by 503
Siu, K., Yuen, K., Castaño-Rodríguez, C., Ye, Z., Yeung, M. L., Fung, S., Yuan, S., Chan, C., Yuen, K., Enjuanes, L., et al. (2019) · The FASEB Journal · doi:10.1096/fj.201802418r · Cited by 500
The role of interleukin‐6 in monitoring severe case of coronavirus disease 2019
Liu, T., Zhang, J., Yang, Y., Ma, H., Li, Z., Zhang, J., Cheng, J., Zhang, X., Zhao, Y., Xia, Z., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202012421 · Cited by 498
Tang, F., Quan, Y., Xin, Z.-T., Wrammert, J., Ma, M.-J., Lv, H., Wang, T.-B., Yang, H., Richardus, J. H., Liu, W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.0903490 · Cited by 496
Human NK cells: surface receptors, inhibitory checkpoints, and translational applications
Sivori, S., Vacca, P., Zotto, G. D., Munari, E., Mingari, M., & Moretta, L. (2019) · Cellular & Molecular Immunology · doi:10.1038/s41423-019-0206-4 · Cited by 493
T Cell Responses to Whole SARS Coronavirus in Humans
Li, C. K., Wu, H., Yan, H., Ma, S., Wang, L., Zhang, M., Tang, X., Temperton, N. J., Weiss, R. A., Brenchley, J. M., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5490 · Cited by 488
Role of PD-1 during effector CD8 T cell differentiation
Ahn, E., Araki, K., Hashimoto, M., Li, W., Riley, J. L., Cheung, J., Sharpe, A. H., Freeman, G. J., Irving, B. A., & Ahmed, R. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718217115 · Cited by 486
Chemokine up-regulation in SARS-coronavirus–infected, monocyte-derived human dendritic cells
Law, H., Cheung, C. Y., Ng, H. Y., Sia, S. F., Chan, Y. O., Luk, W., Nicholls, J. M., Peiris, M. J. S., & Lau, Y. (2005) · Blood · doi:10.1182/blood-2004-10-4166 · Cited by 470
Shi, C.-S., Qi, H.-Y., Boularan, C., Huang, N., Abu-Asab, M. S., Shelhamer, J. H., & Kehrl, J. H. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1303196 · Cited by 469
Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig
Lei, C., Qian, K., Tian, L., Zhang, S., Fu, W., Ding, M., & Hu, S. (2020) · Nature Communications · doi:10.1038/s41467-020-16048-4 · Cited by 462
Cheung, C. Y., Poon, L. L. M., Ng, I. H. Y., Luk, W., Sia, S. F., Wu, M. H. S., Chan, K., Yuen, K., Gordon, S., Guan, Y., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.12.7819-7826.2005 · Cited by 461
Relationship between the ABO Blood Group and the COVID-19 SusceptibilityPreprint
Zhao, J., Yang, Y., Huang, H.-P., et al. (2020) · medRxiv · doi:10.1101/2020.03.11.20031096 · Cited by 454
Chen, Y. Z., Cai, H., Pan, J., Xiang, N., Tien, P., Ahola, T., & Guo, D. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808790106 · Cited by 454
Chu, H., Zhou, J., Wong, B. H.-Y., Li, C., Chan, J. F.-W., Cheng, Z.-S., Yang, D., Wang, D., Lee, A. C.-Y., Li, C., et al. (2016) · Journal of Infectious Diseases · doi:10.1093/infdis/jiv380 · Cited by 448
Is COVID-19 receiving ADE from other coronaviruses?
Tetro, J. A. (2020) · Microbes and Infection · doi:10.1016/j.micinf.2020.02.006 · Cited by 439
Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection
Ng, O.-W., Chia, A., Tan, A. T., Jadi, R. S., Leong, H. N., Bertoletti, A., & Tan, Y.-J. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.02.063 · Cited by 436
Gao, T., Hu, M., Zhang, X., Li, H., Zhu, L., Liu, H., Dong, Q., Zhang, Z., Wang, Z., Hu, Y., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1101/2020.03.29.20041962 · Cited by 435
Multiple Enzymatic Activities Associated with Severe Acute Respiratory Syndrome Coronavirus Helicase
Ivanov, K. A., Thiel, V., Dobbe, J. C., van der Meer, Y., Snijder, E. J., & Ziebuhr, J. (2004) · Journal of Virology · doi:10.1128/jvi.78.11.5619-5632.2004 · Cited by 430
Antiviral activities of type I interferons to SARS-CoV-2 infection
Mantlo, E., Bukreyeva, N., Maruyama, J., Paessler, S., & Huang, C. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104811 · Cited by 430
Zhou, J., Chu, H., Li, C., Wong, B. H., Cheng, Z., Poon, V. K., Sun, T., Lau, C. C.-Y., Wong, K. K. Y., Chan, J. Y. W., et al. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit504 · Cited by 425
COVID19 coagulopathy in Caucasian patients
Fogarty, H., Townsend, L., Cheallaigh, C. N., Bergin, C. J., Martín‐Loeches, I., Browne, P., Bacon, C. L., Gaule, R., Gillett, A., Byrne, M., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16749 · Cited by 418
Devaraj, S. G., Wang, N., Chen, Z., Chen, Z., Tseng, M., Barretto, N., Lin, R., Peters, C. J., Tseng, C.-T. K., Baker, S. C., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704870200 · Cited by 411
In Vitro Reconstitution of SARS-Coronavirus mRNA Cap Methylation
Bouvet, M., Debarnot, C., Imbert, I., Selisko, B., Snijder, E. J., Canard, B., & Decroly, É. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000863 · Cited by 411
A two-pronged strategy to suppress host protein synthesis by SARS coronavirus Nsp1 protein
Kamitani, W., Huang, C., Narayanan, K., Lokugamage, K. G., & Makino, S. (2009) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1680 · Cited by 410
Cao, W., Liu, X., Bai, T., Fan, H., Hong, K., Song, H., Han, Y., Lin, L., Ruan, L., & Li, T. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa102 · Cited by 407
Kim, E., Erdös, G., Huang, S., Kenniston, T. W., Balmert, S. C., Carey, C. D., Raj, V. S., Epperly, M. W., Klimstra, W. B., Haagmans, B. L., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102743 · Cited by 405
Control of coronavirus infection through plasmacytoid dendritic-cell–derived type I interferon
Cervantes‐Barragán, L., Züst, R., Weber, F., Spiegel, M., Lang, K. S., Akira, S., Thiel, V., & Ludewig, B. (2006) · Blood · doi:10.1182/blood-2006-05-023770 · Cited by 402
Shi, C.-S., Nabar, N. R., Huang, N., & Kehrl, J. H. (2019) · Cell Death Discovery · doi:10.1038/s41420-019-0181-7 · Cited by 402
Cameron, M. J., Ran, L., Xu, L., Danesh, A., Bermejo-Martin, J. F., Cameron, C. M., Muller, M. P., Gold, W. L., Richardson, S. E., Poutanen, S. M., et al. (2007) · Journal of Virology · doi:10.1128/jvi.00527-07 · Cited by 386
Bhattacharya, M., Sharma, A. R., Patra, P., Ghosh, P., Sharma, G., Patra, B. C., Lee, S., & Chakraborty, C. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25736 · Cited by 383
Deng, X., Hackbart, M., Mettelman, R. C., O’Brien, A., Mielech, A. M., Yi, G., Kao, C. C., & Baker, S. C. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1618310114 · Cited by 380
Feng, Z., Diao, B., Wang, R., Wang, G., Wang, C., Tan, Y., Liu, L., Wang, C., Liu, Y., Liu, Y., et al. (2020) · medRxiv · doi:10.1101/2020.03.27.20045427 · Cited by 375
Frieman, M. B., Ratia, K. M., Johnston, R. E., Mesecar, A. D., & Baric, R. S. (2009) · Journal of Virology · doi:10.1128/jvi.02220-08 · Cited by 371
Disappearance of Antibodies to SARS-Associated Coronavirus after Recovery
Cao, W.-C., Liu, W., Zhang, P.-H., Zhang, F., & Richardus, J. H. (2007) · New England Journal of Medicine · doi:10.1056/nejmc070348 · Cited by 367
Yang, Z., Liu, J., Zhou, Y., Zhao, Q., Zhao, Q., & Liu, J. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.03.062 · Cited by 364
Huang, C., Lokugamage, K. G., Rozovics, J. M., Narayanan, K., Semler, B. L., & Makino, S. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002433 · Cited by 353
ABO Blood Group and Susceptibility to Severe Acute Respiratory Syndrome
Cheng, Y., Cheng, Y., Cheng, G. Y.-M., et al. (2005) · JAMA · doi:10.1001/jama.293.12.1450-c · Cited by 353
Ahn, J. Y., Sohn, Y., Lee, S. H., Cho, Y., Hyun, J. H., Baek, Y. J., Jeong, S. J., Kim, J. H., Ku, N. S., Yeom, J., et al. (2020) · Journal of Korean Medical Science · doi:10.3346/jkms.2020.35.e149 · Cited by 352
Self-citationCorticosteroid treatment of patients with coronavirus disease 2019 ( COVID ‐19)
Zha, L., Li, S., Lingling, P., Tefsen, B., Li, Y., French, N., Chen, L., Yang, G., & Villanueva, E. (2020) · The Medical Journal of Australia · doi:10.5694/mja2.50577 · Cited by 349
Wathelet, M. G., Orr, M., Frieman, M. B., & Baric, R. S. (2007) · Journal of Virology · doi:10.1128/jvi.00702-07 · Cited by 339
Liu, Y., Sun, W., Guo, Y., Chen, L., Zhang, L., Su, Z., Long, D., & Yu, L. (2020) · Platelets · doi:10.1080/09537104.2020.1754383 · Cited by 333
Chen, X., Li, R., Pan, Z., Qian, C., Yang, Y., You, R., Zhao, J., Liu, P., Gao, L., Li, Z., et al. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-0426-7 · Cited by 327
Regulatory T Cell Specificity Directs Tolerance versus Allergy against Aeroantigens in Humans
Bacher, P., Heinrich, F., Stervbo, U., Nienen, M., Vahldieck, M., Iwert, C., Vogt, K., Kollet, J., Babel, N., Sawitzki, B., et al. (2016) · Cell · doi:10.1016/j.cell.2016.09.050 · Cited by 319
Prognostic value of NT-proBNP in patients with severe COVID-19
Gao, L., Jiang, D., Wen, X., Cheng, X., Sun, M. J., He, B., You, L., Peng, L., Tan, X., Qin, S., et al. (2020) · Respiratory Research · doi:10.1186/s12931-020-01352-w · Cited by 310
Modjarrad, K., Roberts, C. C., Mills, K. T., Castellano, A. R., Paolino, K. M., Muthumani, K., Reuschel, E. L., Robb, M. L., Racine, T., Oh, M., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30266-x · Cited by 308
Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia
Kamphuis, E., Junt, T., Waibler, Z., Forster, R., & Kalinke, U. (2006) · Blood · doi:10.1182/blood-2006-06-027599 · Cited by 306
Viral Kinetics and Antibody Responses in Patients with COVID-19Preprint
Tan, W., Lu, Y., Zhang, J., Wang, J., Dan, Y., Tan, Z., He, X., Qian, C., Sun, Q., Hu, Q., et al. (2020) · medRxiv · doi:10.1101/2020.03.24.20042382 · Cited by 306
Hu, Y., Li, W., Gao, T., Cui, Y., Jin, Y., Li, P., Ma, Q., Liu, X. E., & Cao, C. (2017) · Journal of Virology · doi:10.1128/jvi.02143-16 · Cited by 294
A Dynamic Immune Response Shapes COVID-19 Progression
Ong, E. Z., Chan, Y. F. Z., Leong, W. Y., Lee, N. M. Y., Kalimuddin, S., Mohideen, S. M. H., Chan, K. S., Tan, A. T., Bertoletti, A., Ooi, E. E., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.03.021 · Cited by 290
Coronavirus endoribonuclease targets viral polyuridine sequences to evade activating host sensors
Hackbart, M., Deng, X., & Baker, S. C. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1921485117 · Cited by 289
Liu, W. Y., Fontanet, A. L., Zhang, P., Zhan, L., Xin, Z., Baril, L., Tang, F., Lv, H., & Cao, W. (2006) · The Journal of Infectious Diseases · doi:10.1086/500469 · Cited by 287
Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies
Zhu, Z., Chakraborti, S., He, Y., Roberts, A., Sheahan, T., Xiao, X., Hensley, L. E., Prabakaran, P., Rockx, B., Sidorov, I. A., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701000104 · Cited by 284
Self-citation(2020) · doi:10.1101/2020.04.15.20066407 · Cited by 278
Siu, K., Kok, K., Ng, M.-H. J., Poon, V. K., Yuen, K., Zheng, B.-J., & Jin, D. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.008227 · Cited by 276
Guilliams, M., Lambrecht, B. N., & Hammad, H. (2013) · Mucosal Immunology · doi:10.1038/mi.2013.14 · Cited by 276
Baruah, V., & Bose, S. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25698 · Cited by 273
Sun, L., Xing, Y., Chen, X., Zheng, Y., Yang, Y., Nichols, D. B., Clementz, M. A., Banach, B. S., Li, K., Baker, S. C., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030802 · Cited by 269
Martin, J. E., Louder, M. K., Holman, L. A., Gordon, I. J., Enama, M. E., Larkin, B. D., Andrews, C. A., Vogel, L., Koup, R. A., Roederer, M., et al. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.09.026 · Cited by 267
Cifaldi, L., Prencipe, G., Caiello, I., Bracaglia, C., Locatelli, F., Benedetti, F. D., & Strippoli, R. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39295 · Cited by 267
Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets
ter Meulen, J., Bakker, A. B. H., van den Brink, E. N., Weverling, G. J., Martina, B. E. E., Haagmans, B. L., Kuiken, T., de Kruif, J., Preiser, W., Spaan, W. J. M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16506-9 · Cited by 266
Identification of Human Single-Domain Antibodies against SARS-CoV-2
Wu, Y., Li, C., Xia, S., Tian, X., Kong, Y., Wang, Z., Gu, C., Zhang, R., Tu, C., Xie, Y., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.04.023 · Cited by 264
Gong, J., Dong, H., Xia, Q., et al. (2020) · medRxiv · doi:10.1101/2020.02.25.20025643 · Cited by 264
Testing the association between blood type and COVID-19 infection, intubation, and deathPreprint
Zietz, M., Zucker, J. E., & Tatonetti, N. P. (2020) · medRxiv · doi:10.1101/2020.04.08.20058073 · Cited by 262
Zhou, Y., Fu, B., Zheng, X., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.02.12.945576 · Cited by 261
NKG2A Complexed with CD94 Defines a Novel Inhibitory Natural Killer Cell Receptor
Brööks, A. G., Posch, P. E., Scorzelli, C. J., Borrego, F., & Coligan, J. E. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.4.795 · Cited by 261
Flagged first, then by citations
Research works printed but not linked: 30
- Bao, 2020, Reinfection could not occur in SARS-CoV-2 infected rhesus macaques, bioRxiv
- Campbell, 2020, Prediction of SARS-CoV-2 epitopes across 9360 HLA class I alleles, bioRxiv
- Chen, 2020, [Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia], Zhonghua Jie He He Hu Xi Za Zhi, 43, 203
- Chen, 2020, Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely associated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients, Clin. Infect. Dis.
- Clementi, 2020, Combined prophylactic and therapeutic use maximizes hydroxychloroquine anti-SARS-CoV-2 effects in vitro, bioRxiv
- Díez, 2020, Currently available intravenous immunoglobulin (Gamunex®-C and Flebogamma® DIF) contains antibodies reacting against SARS-CoV-2 antigens, bioRxiv
- Gao, 2020, Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation, medRxiv
- Guo, 2020, Tocilizumab treatment in severe COVID-19 patients attenuates the inflammatory storm incited by monocyte centric immune interactions revealed by single-cell analysis, bioRxiv
- Hulme, 2020, A Bayesian reanalysis of the effects of hydroxychloroquine and azithromycin on viral carriage in patients with COVID-19, medRxiv
- Konig, 2020, Targeting the catecholamine-cytokine axis to prevent SARS-CoV-2 cytokine storm syndrome, medRxiv
- Lei, 2020, The phenotypic changes of γδ T cells in COVID-19 patients, medRxiv
- Li, 2020, Radiographic Findings and other Predictors in Adults with Covid-19, medRxiv
- Liu, 2020, Persistent SARS-CoV-2 presence is companied with defects in adaptive immune system in non-severe COVID-19 patients, medRxiv
- Lokugamage, 2020, SARS-CoV-2 is sensitive to type I interferon pretreatment, bioRxiv
- Lon, 2020, Prediction and Evolution of B Cell Epitopes of Surface Protein in SARS-CoV-2, bioRxiv
- Lou, 2020, Serology characteristics of SARS-CoV-2 infection since the exposure and post symptoms onset, medRxiv
- Lu, 2020, Adjuvant corticosteroid therapy for critically ill patients with COVID-19, medRxiv
- Pan, 2020, Immunoglobulin fragment F(ab’)2 against RBD potently neutralizes SARS-CoV-2 in vitro, bioRxiv
- Pei, 2020, Convalescent Plasma to Treat COVID-19: Chinese Strategy and Experiences, medRxiv
- Poor, 2020, COVID-19 Critical Illness Pathophysiology Driven by Diffuse Pulmonary Thrombi and Pulmonary Endothelial Dysfunction Responsive to Thrombolysis, medRxiv
- Renieri, 2020, ACE2 variants underlie interindividual variability and susceptibility to COVID-19 in Italian population, medRxiv
- Shamshirian, 2020, Hydroxychloroquine Versus COVID-19: A Rapid Systematic Review and Meta-Analysis, medRxiv
- Shao, 2020, Clinical Efficacy of Intravenous Immunoglobulin Therapy in Critical Patients with COVID-19: A multicenter retrospective cohort study, medRxiv
- Tang, 2020, Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial, medRxiv
- Wang, 2020, The definition and risks of Cytokine Release Syndrome-Like in 11 COVID-19-Infected Pneumonia critically ill patients: Disease Characteristics and Retrospective Analysis, medRxiv
- Xiong, 2020, Novel and potent inhibitors targeting DHODH, a rate-limiting enzyme in de novo pyrimidine biosynthesis, are broad-spectrum antiviral against RNA viruses including newly emerged coronavirus SARS-CoV-2, bioRxiv
- Yan, 2020, Prediction of criticality in patients with severe Covid-19 infection using three clinical features: a machine learning-based prognostic model with clinical data in Wuhan, medRxiv
- Zhang, 2020, Treatment With Convalescent Plasma for Critically Ill Patients With SARS-CoV-2 Infection, Chest, 10.1016/j.chest.2020.03.039 · DOI
- Zhang, 2020, Serological detection of 2019-nCoV respond to the epidemic: A useful complement to nucleic acid testing, medRxiv
- Zhao, 2020, LY6E Restricts the Entry of Human Coronaviruses, including the currently pandemic SARS-CoV-2, bioRxiv
Cited by
Sorted by citations
RETRACTED: 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study
Huang, C., Huang, L., Wang, Y., Li, X., Ren, L., Gu, X., Kang, L., Guo, L., Liu, M., Zhou, X., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32656-8 · Cited by 4,084
RetractedRydyznski Moderbacher, C., Ramirez, S. I., Dan, J. M., Grifoni, A., Hastie, K. M., Weiskopf, D., Belanger, S., Abbott, R. K., Kim, C., Choi, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.038 · Cited by 1,790
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurus, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2814-7 · Cited by 1,977
Mathew, D., Giles, J. R., Baxter, A. E., Oldridge, D. A., Greenplate, A. R., Wu, J. E., Alanio, C., Kuri-Cervantes, L., Pampena, M. B., D’Andrea, K., et al. (2020) · Science · doi:10.1126/science.abc8511 · Cited by 1,509
Self-citationIL-6 in inflammation, autoimmunity and cancer
Hirano, T. (2021) · International Immunology · doi:10.1093/intimm/dxaa078 · Cited by 1,453
“Consistent with the notion that severe COVID-19 is a cytokine storm syndrome (12–17, 336 ), SARS-CoV-1 and MERS-CoV activate NF-κ B in a manner dependent on MyD88 through PRRs, such as retinoic acid-inducible gene I protein (RIG-I) and melanoma differentiation-associated protein 5 (MDA5), leading…”
Background
Metadata
- Authors
- Vabret, N., Britton, G. J., Gruber, C., Hegde, S., Kim, J., Kuksin, M., Levantovsky, R., Malle, L., Moreira, A., Park, M. D., Pia, L., Risson, E., Saffern, M., Salomé, B., Esai Selvan, M., Spindler, M. P., Tan, J., van der Heide, V., Gregory, J. K., Alexandropoulos, K., Bhardwaj, N., Brown, B. D., Greenbaum, B., Gümüş, Z. H., Homann, D., Horowitz, A., Kamphorst, A. O., Curotto de Lafaille, M. A., Mehandru, S., Merad, M., Samstein, R. M., Agrawal, M., Aleynick, M., Belabed, M., Brown, M., Casanova-Acebes, M., Catalan, J., Centa, M., Charap, A., Chan, A., Chen, S. T., Chung, J., Bozkus, C. C., Cody, E., Cossarini, F., Dalla, E., Fernandez, N., Grout, J., Ruan, D. F., Hamon, P., Humblin, E., Jha, D., Kodysh, J., Leader, A., Lin, M., Lindblad, K., Lozano-Ojalvo, D., Lubitz, G., Magen, A., Mahmood, Z., Martinez-Delgado, G., Mateus-Tique, J., Meritt, E., Moon, C., Noel, J., O’Donnell, T., Ota, M., Plitt, T., Pothula, V., Redes, J., Reyes Torres, I., Roberto, M., Sanchez-Paulete, A. R., Shang, J., Schanoski, A. S., Suprun, M., Tran, M., Vaninov, N., Wilk, C. M., Aguirre-Ghiso, J., Bogunovic, D., Cho, J., Faith, J., Grasset, E., Heeger, P., Kenigsberg, E., Krammer, F., & Laserson, U.
- Affiliations
- Icahn School of Medicine at Mount Sinai (US)
- Corresponding author
- Vabret, Nicolas
- Samstein, Robert M.
- ORCID
- Vabret, Nicolas
- Britton, Graham J.
- Gruber, Conor
- Hegde, Samarth
- Kuksin, Maria
- Levantovsky, Rachel
- Malle, Louise
- Moreira, Alvaro
- Park, Matthew D.
- Pia, Luisanna
- Risson, Emma
- Saffern, Miriam
- Salomé, Bérengère
- Spindler, Matthew P.
- Tan, Jessica
- van der Heide, Verena
- Bhardwaj, Nina
- Brown, Brian D.
- Greenbaum, Benjamin
- Homann, Dirk
- Horowitz, Amir
- Kamphorst, Alice O.
- Mehandru, Saurabh
- Samstein, Robert M.
- Agrawal, Manasi
- Aleynick, Mark
- Belabed, Meriem
- Brown, Matthew
- Centa, Monica
- Charap, Andrew
- Chen, Steven T.
- Bozkus, Cansu Cimen
- Cody, Evan
- Cossarini, Francesca
- Fernandez, Nicolas
- Grout, John
- Ruan, Dan Fu
- Hamon, Pauline
- Jha, Divya
- Kodysh, Julia
- Leader, Andrew
- Lin, Matthew
- Lindblad, Katherine
- Lubitz, Gabrielle
- Magen, Assaf
- Mahmood, Zafar
- Mateus-Tique, Jaime
- Moon, Chang
- Noel, Justine
- Ota, Miyo
- Plitt, Tamar
- Pothula, Venu
- Redes, Jamie
- Schanoski, Alessandra Soares
- Suprun, Maria
- Tran, Michelle
- Vaninov, Natalie
- Wilk, C. Matthias
- Bogunovic, Dusan
- Cho, Judy
- Faith, Jeremiah
- Grasset, Emilie
- Heeger, Peter
- Kenigsberg, Ephraim
- Krammer, Florian
- Laserson, Uri
- Venue
- Immunity
- Publisher
- Elsevier BV
- Published
- 2020-06
- Volume
- 52
- Issue
- 6
- Pages
- 910-941
- ISSN
- 1074-7613 (ISSN-L)
- PMC
- PMC7200337
- OpenAlex
- W3022878099
- Cited by
- 1,623
- References
- 336
- Citations by year
- 2026: 34 · 2025: 54 · 2024: 113 · 2023: 160 · 2022: 286 · 2021: 567 · 2020: 406
- FWCI
- 16.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Immunity (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Innate Pharma
- Burroughs Wellcome Fund
- Genentech
- Parker Institute for Cancer Immunotherapy
- National Cancer Institute
- Regeneron Pharmaceuticals
- National Institutes of Health (R01AI081848)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Keywords
- COVID-19 pandemic, SARS-CoV-2, innate immune response, adaptive immune response, disease severity, mortality, immunotherapy, antiviral therapy, clinical trials, pathophysiology
- MeSH terms
- Betacoronavirus, COVID-19, SARS-CoV-2, Animals, Disease Susceptibility, Humans, Immunity, Innate, Immunologic Memory, Inflammation, Lymphocytes, Pneumonia, Viral, Coronavirus Infections, Myeloid Cells, Pandemics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review